Related Experiment Video
Updated: Mar 25, 2026

08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
14.7K
Case Report: Conversion of a Low-Flow to High-Flow Priapism
David Cahn1, Elliot Courter1, Gregory Diorio1
1Department of Urology, Einstein Healthcare Network, Philadelphia, PA., USA.
Current Urology
|February 19, 2016
Summary
Priapism, an erection lasting over 4 hours, can shift subtypes. This case details a rare conversion from low-flow to high-flow priapism following a distal shunting procedure.
Area of Science:
- Urology
- Andrology
- Medical Case Reports
Background:
- Priapism is defined as an erection lasting more than 4 hours.
- It is classified into three subtypes: ischemic (low-flow), stuttering, and non-ischemic (high-flow).
- Prompt diagnosis and management are crucial for preserving erectile function.
Observation:
- This report presents a rare case of priapism.
- The patient experienced a conversion from a low-flow priapism to a high-flow priapism.
- This transformation occurred after undergoing a distal shunting procedure.
Findings:
- The conversion from low-flow to high-flow priapism following a distal shunt is an uncommon event.
- Documented cases of this specific phenomenon are scarce in medical literature.
- Diagnostic confirmation relies on clinical suspicion, penile cavernosal blood gas analysis, and Doppler ultrasound.
Implications:
- This case highlights the importance of considering dynamic changes in priapism subtypes post-intervention.
- Further research into the mechanisms and management of such conversions may be warranted.
- Clinicians should maintain a high index of suspicion for evolving priapism presentations.
Related Concept Videos
Urodynamic Studies: Uroflowmetry
7.2K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
7.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
597
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
597
Autoregulation of Blood Flow
8.8K
Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation....
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation....
8.8K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
712
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
712

